Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
96%
Lung Cancer
29%
Progression Free Survival
28%
Gefitinib
27%
Epidermal Growth Factor Receptor Kinase Inhibitor
24%
Lung Adenocarcinoma
21%
Entrectinib
20%
Neoplasm
20%
Disease
18%
Erlotinib
18%
Overall Survival
17%
Chemotherapy
15%
Osimertinib
15%
Protein Tyrosine Kinase Inhibitor
14%
Adverse Event
11%
Adenocarcinoma
10%
Brain Metastasis
9%
Disease Exacerbation
9%
Ramucirumab
8%
Placebo
8%
Lorlatinib
6%
Crizotinib
6%
Malignant Neoplasm
6%
Solid Malignant Neoplasm
6%
Durvalumab
5%
Nivolumab
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
89%
Epidermal Growth Factor Receptor
63%
Lung Cancer
35%
Gefitinib
24%
Entrectinib
23%
Lung Adenocarcinoma
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Progression Free Survival
20%
Non-Small Cell Lung Cancer
18%
Metastatic Carcinoma
16%
Neoplasm
16%
Overall Survival
16%
Disease
15%
Adenocarcinoma
12%
Prognostic Factor
9%
Cerebrospinal Fluid
9%
Osimertinib
9%
Liquid Biopsy
9%
Malignant Neoplasm
9%
Next Generation Sequencing
8%
Radiation Therapy
8%
Computer Assisted Tomography
8%
Arm
7%
Adverse Event
7%
Cancer Cell
7%
Tyrosine-Kinase Inhibitor
7%
Cell-Free DNA
6%
Lorlatinib
6%
Systemic Therapy
6%
Crizotinib
6%
Predictive Factor
6%
Circulating Tumor Cell
5%
Solid Malignant Neoplasm
5%
Low Drug Dose
5%
Multivariate Analysis
5%
Central Nervous System Metastasis
5%
Pleura Effusion
5%